CD22 and acute lymphoblastic leukemia: Moreover, Bueno et al. found that CD34 + CD19-CD22+ leukemic cells were already present at diagnosis and relapse in the bone marrow samples of 70% of patients with B-ALL and that this frequency doubles in patients who achieved CR after CD19-targeting CAR T-cells [61].